NYMXF — Nymox Pharmaceutical Share Price
0.000.00%
Last trade - 00:00- $27.98m
- $27.91m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | n/a | ||
| Return on Equity | n/a | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2018 | 2019 | 2020 | 2021 | 2022 | 2023E | 2024E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 0.3 | 0.12 | 0.01 | n/a | n/a | n/a | n/a | -100% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Nymox Pharmaceutical Corporation is a Canada-based biopharmaceutical company focused on developing its drug candidate, NX-1207, for treating benign prostatic hyperplasia (BPH) and low-grade localized prostate cancer. The Company’s activities and resources have been directed primarily at developing certain pharmaceutical technologies. Its products include Fexapotide Triflutate, NicAlert and TobacAlert. Fexapotide Triflutate is a protein injectable for benign prostatic hyperplasia (BPH) and for low grade localized prostate cancer. NicAlert is a simple test to determine smoking status. TobacAlert is a home test that provides an on-the-spot determination of a person’s level of exposure to tobacco products, including secondhand smoke. The Company started two pivotal double-blind placebo-controlled Phase III trials for NX-1207, NX02-0017 and NX02-0018, conducted at investigational sites across the United States with a total enrollment of approximately 1,000 patients.
Directors
- Paul Averback CHM (70)
- Erik Danielsen CFO (57)
- Randall Lanham GCN (56)
- Richard Cutler IND (63)
- David Morse IND (64)
- James Robinson IND (85)
- Last Annual
- December 31st, 2022
- Last Interim
- September 30th, 2023
- Incorporated
- December 31st, 2015
- Public Since
- November 26th, 1997
- No. of Employees
- 3
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Pink Sheets on Nasdaq
- Shares in Issue
- 93,265,000
- Address
- St. Laurent, SAINT-LAURENT, H4M 2V2
- Web
- https://nymox.com/
- Phone
- Auditors
- TPS Thayer, LLC
Upcoming Events for NYMXF
Q1 2024 Nymox Pharmaceutical Corp Earnings Release
Nymox Pharmaceutical Corp Annual Shareholders Meeting
Q2 2024 Nymox Pharmaceutical Corp Earnings Release
Similar to NYMXF
Acorda Therapeutics
Pink Sheets on Nasdaq
Actavia Life Sciences
Pink Sheets on Nasdaq
Acura Pharmaceuticals
Pink Sheets on Nasdaq
Adhera Therapeutics
Pink Sheets on Nasdaq
Ramoil Management
Pink Sheets on Nasdaq
FAQ
What is the Nymox Pharmaceutical share price?
As of Today at 19:16 UTC, shares in Nymox Pharmaceutical are trading at $0.30. This share price information is delayed by 15 minutes.
How has the Nymox Pharmaceutical share price performed this year?
Shares in Nymox Pharmaceutical last closed at $0.30 and the price had moved by -36.17% over the past 365 days. In terms of relative price strength the Nymox Pharmaceutical share price has underperformed the S&P500 Index by -44.87% over the past year.
What are the analyst and broker recommendations for Nymox Pharmaceutical?
There is no consensus recommendation for this security.
What is the Nymox Pharmaceutical dividend yield?
Nymox Pharmaceutical does not currently pay a dividend.
Does Nymox Pharmaceutical pay a dividend?
Nymox Pharmaceutical does not currently pay a dividend.
When does Nymox Pharmaceutical next pay dividends?
Nymox Pharmaceutical does not currently pay a dividend.
How do I buy Nymox Pharmaceutical shares?
To buy shares in Nymox Pharmaceutical you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Nymox Pharmaceutical?
As of the previous close price of $0.30, shares in Nymox Pharmaceutical had a market capitalisation of $27.98m.
Where are Nymox Pharmaceutical shares listed?
Here are the trading details for Nymox Pharmaceutical:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: NYMXF
What kind of share is Nymox Pharmaceutical?
Based on an overall assessment of its quality, value and momentum Nymox Pharmaceutical is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Nymox Pharmaceutical share price forecast for 2024?
We could not find analyst target price data for this security.
What is the trend in the Nymox Pharmaceutical share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Nymox Pharmaceutical. Over the past six months, its share price has underperformed the S&P500 Index by -74.97%.
As of the last closing price of $0.30, shares in Nymox Pharmaceutical were trading -51.74% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Nymox Pharmaceutical PE Ratio?
The Nymox Pharmaceutical PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.30.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Nymox Pharmaceutical?
Nymox Pharmaceutical's management team is headed by:
- Paul Averback - CHM
- Erik Danielsen - CFO
- Randall Lanham - GCN
- Richard Cutler - IND
- David Morse - IND
- James Robinson - IND